Have a personal or library account? Click to login

Nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson’s disease

Revista Romana de Medicina de Laborator
Volume 22 (2014): Issue 2 (June 2014)
By:
Open Access
|Jun 2014

References

  1. 1. European Association for the Study of the Liver: EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671-85.10.1016/j.jhep.2011.11.007
    Search in Google Scholar
  2. 2. Delangle P, Mintz E.Chelation therapy in Wilson’s disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. DaltonTrans. 2012;41(21):6359-70. doi: 10.1039/c2dt12188c10.1039/c2dt12188c
    Search in Google Scholar
  3. 3. Sözeri E, Feist D, Ruder H, Schärer K. Proteinuria and other renal functions in Wilson’s disease. Pediatr Nephrol. 1997;11(3):307-11. PMID:920317810.1007/s004670050282
    Search in Google Scholar
  4. 4. Mareček Z, Brůha R. Wilsons disease. Vnitr Lek. 2013; 59(7):578-83. PMID:23909262
    Search in Google Scholar
  5. 5. Ranucci G, Di Dato F, Spagnuolo MI, Vajro P, Iorio R.Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J Rare Dis. 2014 Mar; 25:9(1):41. doi: 10.1186/1750-1172-9-4110.1186/1750-1172-9-41
    Search in Google Scholar
  6. 6. Siafakas CG, Jonas MM, Alexander S, Herrin J, Furuta GT. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson’s disease. Am J Gastroenterol.1998 Dec; 93(12):2544-6.PMID:986042310.1111/j.1572-0241.1998.00715.x
    Search in Google Scholar
  7. 7. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML.Wilson’s disease. Lancet. 2007 Feb 3;369(9559):397-408. PMID:17276780
    Search in Google Scholar
  8. 8. Khalil-Manesh F, Price RG. Effect of D-penicillamine on glomerular basement membrane, urinary N-acetyl- beta-D-glucosaminidase and protein excretion in rats. Toxicology. 1983;26(3-4):325-34.10.1016/0300-483X(83)90093-8
    Search in Google Scholar
  9. 9. Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther. 2009; 29(9):947-58. doi: 10.1111/j.1365-2036.2009.03959.x10.1111/j.1365-2036.2009.03959.x
    Search in Google Scholar
  10. 10. Das SK, Ray K. Wilson’s Disease: An Update. Nat Clin Pract Neurol. 2006;2(9):482-493. PMID:1693261310.1038/ncpneuro0291
    Search in Google Scholar
  11. 11. Chang H, Xu A, Chen Z, Zhang Y, Tian F, Li T.Longterm effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson’s disease in children. Exp Ther Med. 2013 Apr;5(4):1129-1132.PMID:23599735 [PubMed] PMCID:PMC362859410.3892/etm.2013.971
    Search in Google Scholar
  12. 12. Grasedyck K. D-penicillamine-side effects, pathogenesis and decreasing the risks. Z Rheumatol. 1988; 47(1):17-9. PMID:3063003
    Search in Google Scholar
  13. 13. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):531-9. doi: 10.1016/j. bpg.2010.07.014
    Search in Google Scholar
  14. 14. Rodríguez B, Burguera J, Berenguer M.Response to different therapeutic approaches in Wilson disease. A long-termfollow up study.Ann Hepatol. 2012 Nov-Dec; 11(6):907-14. PMID: 2310945510.1016/S1665-2681(19)31417-6
    Search in Google Scholar
  15. 15. Ping CC, Hassan Y, Aziz NA, Ghazali R, Awaisu A.Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson’s disease. J Clin Pharm Ther. 2007 Feb;32(1):101-7. PMID: 1728679410.1111/j.1365-2710.2007.00794.x
    Search in Google Scholar
  16. 16. Dong QY, Wu ZY. Advance in the pathogenesis and treatment of Wilson disease. Transl Neurodegener. 2012 Nov;1(1):23. doi: 10.1186/2047-9158-1-2310.1186/2047-9158-1-23
    Search in Google Scholar
  17. 17. Lowette KF, Desmet K, Witters P, Laleman W, Verslype C, Nevens F, et al. Wilson’s disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.Eur J Gastroenterol Hepatol. 2010 May;22(5):564-71. doi: 10.1097/MEG.0b013e3283353df810.1097/MEG.0b013e3283353df8
    Search in Google Scholar
  18. 18. Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, et al. EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson Disease. Clin Gastroenterol Hepatol.2013; 11(8):1028-35. e1-2. doi: 10.1016/j.cgh.2013.03.01210.1016/j.cgh.2013.03.012
    Search in Google Scholar
  19. 19. Członkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014 Apr;21(4):599-606. doi: 10.1111/ ene.1234810.1111/ene.12348
    Search in Google Scholar
  20. 20. Sternlieb I, Scheinberg H. Prevention of Wilson’s Disease in Asymptomatic Patients. N Engl J Med. 1968;278:352-9. PMID: 563564610.1056/NEJM196802152780702
    Search in Google Scholar
  21. 21. Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med. 2006 Aug;17(5):343-8. PMID: 1686401010.1016/j.ejim.2006.03.001
    Search in Google Scholar
  22. 22. Scheinberg IH, Sternlieb I. Wilson disease. in Major problems in internal medicine. eds Lloyd H, Smith J (Saunders, Philadelphia), 1984; 134-49
    Search in Google Scholar
  23. 23. Adams DA, Goldman R, Maxwell MH, Latta H. Nephrotic Syndrome Associated with Penicillamine Therapy of Wilson’s Disease. Am J Med. 1964 Feb;36:330-6. PMID: 1412470010.1016/0002-9343(64)90096-8
    Search in Google Scholar
  24. 24. Tesar V, Zima T, Kalousová M. Pathobiochemistry of nephrotic syndrome. Adv Clin Chem. 2003;37:173-218. PMID: 1261970810.1016/S0065-2423(03)37009-X
    Search in Google Scholar
  25. 25. Ozçakar Z, Ekim M, Ensari A, Kuloglu Z, Yüksel S, Acar B, et al. Membranoproliferative glomerulonephritis in a patient with Wilson’s disease. J Nephrol. 2006;19(6):831-3. PMID: 17173260
    Search in Google Scholar
  26. 26. Koraishy FM, Cohen RA, Israel GM, Dahl NK. Cystic Kidney Disease in a Patient With Systemic Toxicity From Long-term d-Penicillamine Use. Am J Kidney Diseases. 2013 Oct; 62(4): 806-809. doi: 10.1053/j. ajkd.2013.04.017
    Search in Google Scholar
  27. 27. Davis P, Bleehen SS. D-penicillamine in the treatment of rheumatoid arthritis and progressive systemic sclerosis. Br J Dermatol. 1976 Jun;94(6):705-11. PMID:77982110.1111/j.1365-2133.1976.tb05174.x779821
    Search in Google Scholar
  28. 28. Dzieżyc K, Karliński M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’sdisease in pre-symptomatic patients. Eur J Neurol. 2014 Feb;21(2):332-7. doi: 10.1111/ene.1232010.1111/ene.12320
    Search in Google Scholar
  29. 29. Sanches MR. Miscellaneous Treatments: Thalidomide, Potassium Iodide, Levamisole, Clofazimine, Colchicine, and D-Penicillamine. Clin Dermatol. 2000;18:131-45. PMID: 1070109510.1016/S0738-081X(99)00103-0
    Search in Google Scholar
  30. 30. Walshe JM. Monitoring copper in Wilson’s disease. Adv Clin Chem. 2010;50:151-63. PMID: 20521445 10.1016/S0065-2423(10)50008-8
    Search in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2014-0016 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 181 - 189
Submitted on: Sep 13, 2013
Accepted on: May 3, 2014
Published on: Jun 21, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Wilson’s disease,
D-penicillamine,
Urinary copper excretion
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2014 Anna D. Kostadinova, Marian Y. Mihaylov, Irena D. Ivanova, Rayna T. Robeva, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 22 (2014): Issue 2 (June 2014)Next article